HCPCS Level II
Outpatient PPS (prospective payment system), temporary
Letter C, 622 codes. CMS HCPCS Level II file dated September 23, 2026.
License: a US government work, in the public domain (Public Domain Mark 1.0).
Run it in Rivvi
Check every code on your export
Upload a claims or charge export. Rivvi flags HCPCS codes that are deleted or replaced, with the replacement and its date.
Check my exportFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Blocks
Each block is one hundred codes. Open one instead of paging the whole letter.
Codes
321 to 360 of 622
- C9038Injection, mogamulizumab-kpkc, 1 mgDeleted 2019
- C9039Injection, plazomicin, 5 mgDeleted 2019
- C9040Injection, fremanezumab-vfrm, 1mgDeleted 2019
- C9041Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mgDeleted 2020
- C9042Injection, bendamustine hcl (belrapzo), 1 mgDeleted 2019
- C9043Injection, levoleucovorin, 1 mgDeleted 2019
- C9044Injection, cemiplimab-rwlc, 1 mgDeleted 2019
- C9045Injection, moxetumomab pasudotox-tdfk, 0.01 mgDeleted 2019
- C9046Cocaine hydrochloride nasal solution (goprelto), 1 mgDeleted 2026
- C9047Injection, caplacizumab-yhdp, 1 mg
- C9048Dexamethasone, lacrimal ophthalmic insert, 0.1 mgDeleted 2019
- C9049Injection, tagraxofusp-erzs, 10 mcgDeleted 2019
- C9050Injection, emapalumab-lzsg, 1 mgDeleted 2019
- C9051Injection, omadacycline, 1 mgDeleted 2019
- C9052Injection, ravulizumab-cwvz, 10 mgDeleted 2019
- C9053Injection, crizanlizumab-tmca, 1 mgDeleted 2020
- C9054Injection, lefamulin (xenleta), 1 mgDeleted 2020
- C9055Injection, brexanolone, 1mgDeleted 2020
- C9056Injection, givosiran, 0.5 mgDeleted 2020
- C9057Injection, cetirizine hydrochloride, 1 mgDeleted 2020
- C9058Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mgDeleted 2020
- C9059Injection, meloxicam, 1 mgDeleted 2020
- C9060Fluoroestradiol f18, diagnostic, 1 mciDeleted 2020
- C9061Injection, teprotumumab-trbw, 10 mgDeleted 2020
- C9062Injection, daratumumab 10 mg and hyaluronidase-fihjDeleted 2020
- C9063Injection, eptinezumab-jjmr, 1 mgDeleted 2020
- C9064Mitomycin pyelocalyceal instillation, 1 mgDeleted 2020
- C9065Injection, romidepsin, non-lyophilized (e.g. liquid), 1mgDeleted 2021
- C9066Injection, sacituzumab govitecan-hziy, 2.5 mgDeleted 2020
- C9067Gallium ga-68, dotatoc, diagnostic, 0.01 mci
- C9068Copper cu-64, dotatate, diagnostic, 1 millicurieDeleted 2021
- C9069Injection, belantamab mafodontin-blmf, 0.5 mgDeleted 2021
- C9070Injection, tafasitamab-cxix, 2 mgDeleted 2021
- C9071Injection, viltolarsen, 10 mgDeleted 2021
- C9072Injection, immune globulin (asceniv), 500 mgDeleted 2021
- C9073Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseDeleted 2021
- C9074Injection, lumasiran, 0.5 mgDeleted 2021
- C9075Injection, casimersen, 10 mgDeleted 2021
- C9076Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseDeleted 2021
- C9077Injection, cabotegravir and rilpivirine, 2mg/3mgDeleted 2021